Earnings call transcript: Judges Scientific H1 2026 profit drops as orders improve

Judges Scientific reported a weak H1 2026, with revenue down 21% year over year to GBP 55.7 million and adjusted EPS down 72% to GBP 0.389, as U.S. research-funding uncertainty, China procurement delays and offshore-wind weakness hit demand. The company cut roughly GBP 2 million of costs, maintained 90% cash conversion, and lifted its interim dividend 10% to 36p, but adjusted net debt rose GBP 3 million and ROTIC fell to about 13%. Order intake improved from -18% in Q1 to -1% year to date by late September, supporting reaffirmed FY2026 expectations, although delivery is heavily Q4-weighted and subject to execution risk. Shares fell 2.38% premarket to $3,720.

Analysis

JDG’s investment case has shifted from a compounding-acquirer multiple to a delivery-risk multiple until the Q4 shipment cycle is complete. The key issue is not whether demand has bottomed, but whether a small number of high-value instruments can be accepted and recognized on schedule; with fixed-cost absorption, a modest revenue shortfall can erase a disproportionate share of the implied H2 earnings recovery. The dividend increase is therefore a weak signal of confidence rather than evidence of sustainable distributable cash flow, given thin interim cover and rising leverage.

The more consequential read-through is differentiation within UK scientific instruments. HLMA should retain a premium relative to JDG because its end-market mix, recurring consumables/service exposure and broader scale reduce single-project revenue-recognition risk. OXIG is directionally exposed to the same academic-budget and China-procurement constraints, but its semiconductor and quantum exposure creates a cleaner upside path if industrial capex remains resilient; JDG’s industrial exposure is presently too small and heterogeneous to offset research volatility.

Over 1-3 months, evidence of China deliveries converting and Q4 execution can drive a sharp relief rally from depressed levels, but that is a trade on operational confirmation, not a valuation call. Over 6-18 months, persistent US research-funding pressure and delayed project revenue lower ROTIC, constraining debt-funded M&A—the mechanism that historically supported JDG’s premium valuation. CFO succession adds a further governance discount if the replacement lacks acquisition underwriting credibility.

Contrarian upside is that the order recovery may be enough to restore operating leverage faster than the market expects, while weaker private instrument vendors could expand the acquisition pipeline. That upside is falsified by any FY26 guidance cut, material working-capital build, net-debt increase beyond normal seasonal needs, or FY27 order intake reverting below flat growth after China normalization.

Key Decisions for Investors

• Remain underweight JDG through Q4 revenue recognition; do not average down solely on the maintained outlook. Reassess after the FY26 update if H2 adjusted EPS delivery and net-debt reduction validate the recovery. A guidance cut or missed shipment milestone is likely to produce further multiple compression.
• Pair trade for 3-6 months: long HLMA / short JDG, sized beta-neutral. HLMA offers superior earnings durability while JDG carries concentrated Q4 execution, academic-funding and CFO-transition risk; cover the JDG short if verified order intake turns sustainably positive and FY26 delivery is achieved.
• Watch OXIG as the higher-beta long expression of industrial science spending, but require confirmation from semiconductor order commentary and Chinese demand before entry. Prefer OXIG over JDG if the thesis is a semicap/battery recovery rather than a normalization of university research budgets.
• Set an event-driven alert on JDG’s FY26 update: initiate a tactical long only if management delivers guidance, converts delayed China orders into cash, and shows lower exit net debt. Target a 15-25% relief move over 1-3 months; exit on any FY27 research-market deterioration or ROTIC failing to stabilize.